Cancer-Causing Toxins and Other Myeloma News

What's Behind the FDA's Closing of Myeloma Immune Therapy Trials?

In his blog this week, IMF Chairman Dr. Brian Durie reports on the recent flurry of myeloma clinical trial closures by the US Food and Drug Administration. “A key problem is that unleashing the immune T-cells with these therapies has allowed the T-cells to attack not just the myeloma, as hoped, but also critical normal tissues, including lung tissues, liver, thyroid, and even heart cells,” he says. “This is unacceptable toxicity.” Also, on the eve of the 16th anniversary of 9/11, another national disaster—Hurricane Harvey—has, like the terrorist attack in New York City, left a slew of cancer-causing toxins in its wake. Read Dr. Durie’s blog.

Lancet Oncology Publishes Data on Overall Survival Benefits from Kyprolis® (carfilzomib) in Phase 3 Endeavor Trial

In a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma, The Lancet Oncology reports “carfilzomib provided a significant and clinically meaningful reduction in the risk of death compared with bortezomib.”

Register NOW for the IMF Patient & Family Seminar in Dallas, Texas

An IMF Patient and Family Seminar will take place during the weekend of October 6th and 7th, 2017 at The Westin Galleria in Dallas, Texas (13340 Dallas Parkway). You may register for one or both days of the event. The expert speakers include Dr. Brian Durie (Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute), Dr. Rafat Abonour (Indiana University School of Medicine), Dr. Craig Cole (Michigan University Cancer Center), Dr. Larry Anderson (UT Southwestern Medical Center) and Dr. Saad Usmani (Levine Cancer Institute).

How to FUNdraise for the IMF Without Leaving Your Home

You have probably heard about the IMF’s Member FUNdraisers. However, you may be too busy to plan an event. Here’s a simple way you can raise myeloma awareness and funding without leaving your home: the IMF’s Letter-Writing Campaign. No amount you raise is too big or too small! The IMF's Director of Member Events Suzanne Battaglia shares this story about letter-writing campaigns: “I was contacted by a young woman who wanted to raise funds in honor of her dad. She confidentially informed me her friends were not wealthy, and she could probably only raise a couple hundred dollars. I reminded her that every penny counts. I was able to call her and tell her that her letter campaign raised more than $20,000. Whether it’s $20 or $20,000, it all adds up!” Contact Suzanne Battaglia today at 1-800-452-2873 or at sbattaglia@myeloma.org, and she will provide you with the letter template to send to your mail or email contacts.

Save the Date: The IMF's 11th Annual Comedy Celebration - Saturday, November 4th, 2017

The IMF’s 11th Annual Comedy Celebration will be held on Saturday, November 4th, 2017 in Los Angeles, CA.  Ray Romano will host a cast of stellar comedians and performers in raising funds for the Peter Boyle Research Fund supporting the IMF’s groundbreaking Black Swan Research Initiative®. This year, we’re excited to announce that members from around the world will be able to participate remotely, as the evening’s silent auction will take place ONLINE simultaneously! To register for the online auction, to receive updates from the event, or to buy tickets, journal ads, or sponsorships, visit the event site at comedy.myeloma.org.

Join This FREE Webinar on Myeloma Tests and Results

Join the IMF’s Medical Editor Debbie Birns for a “Living Well with Myeloma” webinar on Making Sense of Tests and Results. Debbie will outline the various tests that are used to diagnose myeloma, monitor response to treatment, and detect side effects. This sixty-minute webinar occurs on Thursday, September 14th, 2017 at 4 PM PT / 7 PM ET and includes a question-and-answer session. Pre-register today for FREE.

Can Darzalex (daratumumab) therapy interfere with response assessment?

In this week’s video, Dr. Brian GM Durie explains how to determine if monoclonal protein spikes in the blood are actually spikes due to daratumumab therapy.

 

 


We Thank Our Sponsors: Amgen, Celgene Corporation, Genentech, Janssen Pharmaceuticals, and Takeda Oncology